Danaher Corporation (DHR) has been benefiting from strength in its Diagnostics segment and accretive acquisitions. The company's measures to reward its shareholders are encouraging. Let's discuss the factors that should influence investors to retain this Zacks Rank #3 (Hold) company for the time being. Growth Catalysts of DHR Business Strength: Strength in Danaher's clinical diagnostics business, driven by growth in Leica Biosystems and Beckman Colter Diagnostics units, has been supporting the Diagnostics s ...

WASHINGTON, Sept. 4, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") confirmed its previously issued guidance for the third quarter and full year 2024 ahead of a previously scheduled analyst event.The Company provides forecasted sales only on a non-GAAP core revenue basis because of the difficulty in estimating the other components of GAAP revenue, such as currency translation, acquisitions and divested product lines.  For both the third quarter and full year 2024, the Company continues ...

WASHINGTON, Aug. 26, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) will host a live video webcast of its Diagnostics Investor and Analyst Meeting in Washington, D.C. on September 5, 2024 beginning at approximately 10:00 a.m. ET. The event will be hosted by Julie Sawyer Montgomery, Executive Vice President, Diagnostics. A link to the webcast and accompanying slide presentation will be available on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentatio ...

PM Images Introduction A blended P/E ratio of 36x. 0% EPS growth in 2024. I think it's fair to say that this does not look like a winning combination. Especially in light of what I wrote in a recent article titled "Buying Wonderful Businesses At Fair Prices - The Billionaire Way," it may be weird that I give you a stock with a lofty valuation and no expected growth in 2024. One of the "Buffett-style" checklist items was to make sure we buy companies trading at a discount. [...] do you fully understand the ...

It has been about a month since the last earnings report for Danaher (DHR) . Shares have added about 2% in that time frame, underperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Danaher due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Danaher Q2 Earnings Beat, Biotechnology Sales Dip Y/YD ...

NSA Digital Archive/E+ via Getty Images Introduction It's time to talk big-picture stuff. However, before I get to the main message, I wanted to share a chart I just came across. As we are currently in a very volatile pre-election period with a load of political uncertainty, Ritholz Wealth Management produced a chart that shows the S&P 500 returns during presidential terms - including the max drawdown. Ritholz Asset Management One thing clearly becomes obvious: (almost) every single president has gone t ...

Danaher Corporation’s (DHR) second-quarter 2024 adjusted earnings (excluding 50 cents from non-recurring items) of $1.72 per share surpassed the Zacks Consensus Estimate of $1.57. The bottom line declined 0.6% year over year.Danaher’s net sales of $5.7 billion outperformed the consensus estimate of $5.6 billion. However, the metric declined 3% year over year due to lower core sales in the Biotechnology segment.Organic sales decreased 3.5%. Acquisitions had a positive impact of 2% on quarterly sales while ad ...

Key TakeawaysDanaher's second-quarter results beat analysts' expectations on both profit and revenue.CEO Rainer Blair cited "positive momentum" in Danaher's bioprocessing business and "strong performance" in molecular testing subsidiary Cepheid.Danaher affirmed its guidance that non-GAAP core revenue will decline by a low-single-digit percentage year-over-year. Danaher Corp. (DHR) beat analysts' expectations on the top and bottom lines with its second-quarter results, sending shares higher in intraday tradi ...

The biotechnology, diagnostics, and life sciences company looks set to return to its long-term growth rate.Danaher's (DHR 7.12%) core revenue decline of 3.5% in the second quarter might not seem like anything to write home about. Still, as ever in investing, it's about context, and the company's earnings report shows that it's set to return to its long-term growth track.The good news encouraged investors to bid the stock up by more than 7% in trading before 10 a.m. ET today.Danaher beats guidanceAs you migh ...

Financial Data and Key Metrics Changes - Sales for Q2 2024 were $5.7 billion, with core revenue declining by 3.5% year-over-year [10] - Gross profit margin for Q2 was 59.7%, and adjusted operating profit margin increased by 60 basis points to 27.3% [10] - Adjusted diluted net earnings per share were $1.72, remaining flat year-over-year [11] - Free cash flow generated in the quarter was $1.1 billion, with a year-to-date free cash flow to net income conversion ratio of 129% [11] Business Line Data and Key Metrics Changes - In the biotechnology segment, core revenue declined by 7%, with bioprocessing down high single digits and discovery and medical business down mid-single digits [12] - Life Sciences segment saw a core revenue decrease of 5.5%, with capital equipment investments remaining constrained [17] - Diagnostics segment experienced a core revenue increase of 3%, driven by mid-single digit growth in Clinical Diagnostics [20] Market Data and Key Metrics Changes - Core revenues in developed markets were down low single digits, while high growth markets declined high single digits, including a high-teens decline in China [10] - Bioprocessing demand in the U.S. and Europe improved, with orders increasing high single digits sequentially [8] - In China, bioprocessing demand remained weak as customers managed liquidity, with expectations for improvement in 2025 [8][55] Company Strategy and Development Direction - Danaher aims for sustainable long-term value creation, expecting high single-digit core revenue growth with a differentiated margin and cash flow profile [9] - The company continues to invest in innovation to support customers in developing life-changing therapeutics [15] - Share repurchases reflect confidence in long-term organic growth, earnings, and cash flow outlook, while maintaining a bias towards M&A for capital deployment [11][44] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the recovery in bioprocessing and the overall market conditions, with expectations for a low single-digit core revenue decline in Q3 2024 [24] - The company anticipates continued improvement in bioprocessing orders and a return to normal order patterns as destocking is largely complete [72] - Management highlighted the importance of the funding environment for smaller biotech customers and the expected impact on order volumes [73] Other Important Information - Danaher released its 2024 Sustainability Report, committing to science-based greenhouse gas emission reduction targets [23] - The company received FDA approvals for new diagnostic tests, enhancing its product offerings and market position [22] Q&A Session Summary Question: Insights on bioprocessing consumables and capital equipment - Management noted that ordering patterns for consumables have returned to normal, while capital equipment remains slightly constrained for smaller customers [29] Question: Q3 guidance and seasonal impacts - Management expects low single-digit revenue decline in bioprocessing for Q3, with normal seasonal patterns anticipated [35][36] Question: Competitive pricing environment - Pricing was up 100 basis points in Q2, with expectations to remain above historical averages for 2024 [51] Question: China market dynamics - Management indicated that increased coding activity in China is not expected to convert to orders until 2025 due to pending stimulus funding [55][76] Question: Life Sciences segment performance - The Life Sciences segment remains under pressure, with capital equipment demand weak and expectations for stabilization in the second half of 2024 [58][59]